• Anlotinib and Multitarget Angiogenesis Inhibition

  2026-09-29

  The reference study shows that anlotinib suppresses angiogenic responses driven by VEGF, PDGF-BB, and FGF-2 by inhibiting VEGFR2, PDGFRβ, FGFR1, and downstream ERK signaling. Its combination of endothelial migration, tube formation, aortic ring, and CAM assays provides a mechanistic framework for evaluating multi-target tyrosine kinase inhibitors in cancer research.

• EZ Cap™ Cas9 mRNA (m1Ψ) for MASLD Assays

  2026-09-29

  Build transient, sequence-specific LSS perturbation models with a Cap1- and m1Ψ-modified Cas9 transcript rather than relying only on small-molecule inhibition or knockdown. This workflow translates recent MASLD mechanism research into practical genome editing in mammalian cells while emphasizing controls, metabolic readouts, and RNA-quality safeguards.

• From Tau Ser356 to Translational Strategy

  2026-09-28

  A translational analysis of tau Ser356 biology, NUAK inhibition, model-specific responses, and the responsible positioning of Linagliptin (BI-1356) in exploratory research workflows.

• BIBP 3226: A Causal Probe for Cardiac Signaling

  2026-09-28

  Explore how BIBP 3226 trifluoroacetate can help researchers test receptor-level contributions to the adipose-neural axis in cardiac arrhythmia models. This article translates recent coculture findings into practical assay decisions while distinguishing NPY and NPFF pharmacology and outlining key controls.

• Anlotinib Suppresses Angiogenesis Through Three RTKs

  2026-09-27

  The study reports that anlotinib inhibits angiogenic responses induced by VEGF, PDGF-BB, and FGF-2, linking reduced endothelial migration and vessel-like structure formation to suppression of VEGFR2, PDGFRβ, FGFR1, and ERK activation. By combining cell-based, aortic-ring, and chick CAM assays, it provides convergent preclinical evidence for a multi-target anti-angiogenic mechanism, while leaving clinical efficacy and tumor-control questions unresolved.

• Caspase-3 Fluorometric Assay Kit in Ferroptosis

  2026-09-26

  The Caspase-3 Fluorometric Assay Kit can help distinguish executioner-caspase activation from other events in ferroptosis–apoptosis crosstalk. Learn how to interpret its DEVD-AFC signal alongside PARP1 findings, orthogonal readouts, and essential assay controls.

• HyperScript III RT SuperMix for CRC qPCR

  2026-09-25

  Turn colorectal cancer biomarker hypotheses into a controlled two-step qRT-PCR workflow, including practical checks for scarce RNA, GC-rich targets, and genomic DNA carryover. The integrated gDNA wiper and broad-coverage primer design are useful for exploratory validation—but the published CRC findings remain research evidence, not a clinical test.

• Ganetespib (STA-9090): Cancer Assay Workflows

  2026-09-25

  Ganetespib (STA-9090) offers a potent, non-geldanamycin approach to Hsp90 inhibition for cancer research, with practical value in dose-response testing and client-protein studies. This guide outlines a reproducible cell-assay workflow, solvent and exposure controls, and a careful way to apply insights from a norovirus secretion study without confusing distinct biological mechanisms.

• Breast Cancer Dependence on MCL-1 Is Apoptotic

  2026-09-24

  In established breast cancer models, genetic deletion or pharmacological inhibition of MCL-1 impaired tumor growth, and the antitumor effects required the pro-apoptotic proteins BAX and BAK. The findings support MCL-1’s canonical role in suppressing mitochondrial apoptosis as a central driver of breast cancer dependence, while clarifying how to interpret stemness associations and test MCL-1 inhibitors.

• Ibrutinib (PCI-32765): BTK Inhibitor Research Guide

  2026-09-24

  Ibrutinib, also called PCI-32765, is an irreversible BTK inhibitor with a reported BTK IC50 of 0.5 nM. This research guide summarizes its B-cell receptor signaling rationale, preclinical CLL findings, product handling information, and the limits of interpreting model data.

• HO Biology Beyond Inhibition: Translational Study Design

  2026-09-24

  Heme oxygenase connects heme turnover with redox biology, creating opportunities—and interpretive challenges—for translational research. This article examines how Tin Mesoporphyrin IX (chloride) can help test HO-dependent hypotheses, and how to interpret inhibition alongside emerging evidence linking HO-1 and ROS modulation to HBV biology.

• AZD3463: ALK/IGF1R Inhibitor Workflows

  2026-09-23

  Build reproducible neuroblastoma experiments around AZD3463, a dual ALK/IGF1R inhibitor suited to mutant-ALK models, pathway analysis, and combination studies. This practical guide connects dosing, signaling readouts, apoptosis assays, and troubleshooting to evidence-backed use cases.

• Ibrexafungerp: From pH Resilience to Translation

  2026-09-22

  A translational framework for positioning Ibrexafungerp and MK 3118 across mechanism, resistance-aware susceptibility testing, preclinical models, and clinical development.

• Sumatriptan Metabolism: CYP and MAO Revisited

  2026-09-22

  The reference study revisits the established view that sumatriptan is metabolized mainly through MAO A and demonstrates additional CYP-mediated N-demethylation. Its recombinant-enzyme and HPLC-MS design provides a practical framework for distinguishing parallel oxidative pathways and interpreting metabolite sequences.

• Prestained Protein Marker: SDS-PAGE Guide

  2026-09-21

  This Prestained Protein Marker provides visible size landmarks from 10–250 kDa for monitoring SDS-PAGE separation and checking Western blot transfer. It is appropriate for denaturing gel and membrane workflows, including EDTA-sensitive Phosbind and fluorescent imaging applications, but it should not be used as a substitute for protein identity, purity, or exact mass confirmation.

7973 records 1/532 page Next 12345 下5页 Last page